Literature DB >> 22707295

Effects of trimethoxystilbene on proliferation and apoptosis of pulmonary artery smooth muscle cells.

Ge Gao1, Xin Wang, Xiaoqun Qin, Xinyu Jiang, Daxiong Xiang, Li Xie, Jianguo Hu, Jiesheng Gao.   

Abstract

Proliferation of pulmonary artery smooth muscle cells (PASMC) is an important contributor to the progress of pulmonary arterial hypertension (PAH). Anti-inflammatory therapies may have therapeutic applicability for PAH. Resveratrol (RES) has prominent anti-inflammatory effects in vitro, but in vivo its beneficial effects are limited by short systemic half life and poor lipotrophy. A derivative of RES, trimethoxystilbene (TMS), has higher lipotropy and extended half life compared with RES, and can potentially overcome the limitations of RES. In the present study, we studied the effects of TMS and RES on proliferation and apoptosis of PASMC stimulated with Tumor Necrosis Factor-α. The effects on PASMC proliferation were quantified by MTT, while apoptosis was assessed by flow cytometry (Annexin V/propidium iodide assay). We observed strong inhibitory effects of TMS on the growth of PASMC, and these effects were 20 times more potent than those of RES. We further documented induction of apoptosis in PASMC treated with TMS, again, to a higher degree than with RES. In conclusion, TMS is more potent than RES in the inhibition of proliferation and induction of apoptosis of PASMC, demonstrating its potentially beneficial role for treating PAH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22707295     DOI: 10.1007/s12013-012-9377-7

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  7 in total

1.  Resveratrol prevents hypoxia-induced arginase II expression and proliferation of human pulmonary artery smooth muscle cells via Akt-dependent signaling.

Authors:  Bernadette Chen; Jianjing Xue; Xiaomei Meng; Jessica L Slutzky; Andrea E Calvert; Louis G Chicoine
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-20       Impact factor: 5.464

2.  Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.

Authors:  Wei Zhuang; Guili Lian; Bangbang Huang; Apang Du; Genfa Xiao; Jin Gong; Changsheng Xu; Huajun Wang; Liangdi Xie
Journal:  Exp Biol Med (Maywood)       Date:  2018-08-12

Review 3.  Resveratrol as a potential therapeutic drug for respiratory system diseases.

Authors:  Xiao-Dan Zhu; Xiao-Ping Lei; Wen-Bin Dong
Journal:  Drug Des Devel Ther       Date:  2017-12-15       Impact factor: 4.162

Review 4.  Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases.

Authors:  Zhuozhuo Li; Liwei Wang; Yuanyuan Ren; Yaoyao Huang; Wenxuan Liu; Ziwei Lv; Lu Qian; Yi Yu; Yuyan Xiong
Journal:  Cell Death Discov       Date:  2022-10-08

Review 5.  Therapeutic Versatility of Resveratrol Derivatives.

Authors:  Waqas Nawaz; Zhongqin Zhou; Sa Deng; Xiaodong Ma; Xiaochi Ma; Chuangang Li; Xiaohong Shu
Journal:  Nutrients       Date:  2017-10-29       Impact factor: 5.717

Review 6.  Medicinal Plants and Phytochemicals for the Treatment of Pulmonary Hypertension.

Authors:  Seyed Vahid Jasemi; Hosna Khazaei; Ina Yosifova Aneva; Mohammad Hosein Farzaei; Javier Echeverría
Journal:  Front Pharmacol       Date:  2020-03-12       Impact factor: 5.810

7.  Trimethoxystilbene Reduces Nuclear Factor Kappa B, Interleukin-6, and Tumor Necrosis Factor-α Levels in Rats with Pulmonary Artery Hypertension.

Authors:  Jie Shu; Wei Liu; Fei Han; Fanyan Luo
Journal:  Biomed Res Int       Date:  2019-11-26       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.